AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
Completed
- Conditions
- SchizophreniaSchizoaffective DisorderRecurrent Depression
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT01028196
- Locations
- 🇷🇺
Research Site, Novosibirsk, Russian Federation
Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR
Completed
- Conditions
- Bipolar DisorderNew Occurred Episode
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 537
- Registration Number
- NCT01029145
- Locations
- 🇷🇴
Research Site, Tulcea, Romania
AZD Single Ascending Dose Study In Healthy Japanese Subjects
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT01028040
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia
Completed
- Conditions
- Undertreatment of Hypercholesterolaemia
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT01027624
- Locations
- 🇿🇦
Research Site, Johannesburg, South Africa
This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT01027234
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 172
- Registration Number
- NCT01026402
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
Early Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Placebo to match Aricept
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 155
- Registration Number
- NCT01024660
- Locations
- 🇿🇦
Research Site, Roodepoort, South Africa
🇨🇦Reearch Site, Quebec, Canada
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Completed
- Conditions
- Prostate CancerOsteoporosis
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2010-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 829
- Registration Number
- NCT01025479
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4053
- Registration Number
- NCT01025388
- Locations
- 🇸🇦
Research Site, Makah, Western, Saudi Arabia
Observational Study To Evaluate Statins Patterns Of Use In Spain
Withdrawn
- Conditions
- Dyslipidemia
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01023503
- Locations
- 🇪🇸
Research Site, Barcelona, Spain